Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added a new press release entry for 06 January 2026: Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity. Removed the Baxdrostat Bax24 Phase III press release dated 09 November 2025.
    Difference
    1%
    Check dated 2026-01-08T02:08:45.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    Added two press releases: Enhertu Breakthrough Therapy Designation (22 December 2025) and LATIFY Phase III trial update; removed two items: 9M and Q3 2025 results and Gefurulimab PREVAIL MG-ADL results.
    Difference
    5%
    Check dated 2025-12-24T15:27:23.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Added two new press releases: Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus (16 December 2025) and Enhertu plus pertuzumab approved in the US as first-line treatment for HER2-positive metastatic breast cancer (15 December 2025). Removed two older items: Alexion data presented at the 2025 AANEM Annual Meeting and MGFA Scientific Session, and Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1 (28–29 October 2025).
    Difference
    5%
    Check dated 2025-12-17T04:10:01.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Added a new press release entry for 04 December 2025 'AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH' and removed the 22 October 2025 entry 'Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps'.
    Difference
    0.9%
    Check dated 2025-12-10T00:40:36.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Two new press releases were added: Baxdrostat New Drug Application accepted under FDA Priority Review (02 December 2025) and Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers (25 November 2025). Two older items were removed: Datroway's reported survival benefit in metastatic triple-negative breast cancer (19 October 2025) and DESTINY-Breast05/Enhertu results reporting (18 October 2025).
    Difference
    5%
    Check dated 2025-12-02T17:27:40.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    Added two new press releases (Maryland investment; Koselugo US NF1 approval) and removed two older items (DESTINY-Breast11 pCR details; Tezspire US approval for CRS with nasal polyps).
    Difference
    5%
    Check dated 2025-11-25T13:43:33.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.